Adipogen/NpFlamma® MMP3,7 774/BCTPNM0206Q010/10 doses

CancercellisinfluencedbyECM(extracellularmatrix),ECM-relatedgrowthfactorsandcytokineandsurroundingcellsinthegrowthprocessofcancercell.Especiallyfourcharacteristicsofcancersuchasmigration,invasion,metastasisandangiogenesisreactaccordingtothesurroundingmicroenvironment.Inthiscase,MMP(matrixmetalloprotease)thatistheproteasecontrolscell-cellandcell-ECMinteractionsplayinganimportantroleinthegrowthofcancercell.AccordinglyanumberofresearcheshavebeenproceedingavarietyofresearchesusingMMP.AsthisproductgeneratesfluorescenceaccordingtotheabsolutevolumeofMMP,itcanbeeffectivelyaccumulatedinthecancertissuesanditispossibleforopticalimagingofthetissueswhereMMPisover-expressed.Asthisproductenablestoquicklycheckactivityandsuppressionofproteasethroughimaging,whichcanbeappliedtodrugscreening,anditispossibleforreal-timebasedcellimagingandnon-invasivetissuesimagingforcellandtissue.Especiallyinadditiontothemethodofscreeningnewdrugsuchasinhibitorthatinhibitsover-expressionofprotease,itcanbeusedusefullyforearlydiagnosisofavarietyofdiseasesandincurablediseaseslikeautoimmunediseasesthatareMMP-relatedcancer,ostarthritis,rheumarthritis,dementia,etc.Inaddition,thisproductsgroupisexpectedtobeeasytouseowingtohavevariousfluorescentwavelengths.   NpFlamma® MMPseriesofBioActsisaproductdevelopedtoactivatefluorescencedependingonthetypesofMMPexpressedinvivo.ItisMMPactivatableimagingagentsthatarecompletedbyapplyingfluorescencetechniqueofFlamma® FluorsandquenchertechniqueofqFlamma® basedonBioActs’patentedtechnologyinpeptides.ApplicationType:Invivo.ParticleSize:250±50nm.Excitation/Emission(nm):793/810nm.